P-55 QUALITY OF LIFE IMPROVES IN PATIENTS WITH OR WITHOUT CIRRHOSIS AFTER HEPATITIS C CURE WITH DIRECT-ACTING ANTIVIRAL AGENTS

Abstract

Background: The effect of the treatment of chronic hepatitis C (CHC) with direct-acting antiviral agents (DAAs) on health- related quality of life (HRQL) has been mostly evaluated in clinical trials, and infrequently in Latin-American patients. Aims: To evaluate the effect of CHC treatment with DAAs on HRQL in patients who achieved sustained virological response (SVR) in a real-life setting. Materials and Methods: Prospective cohort study of consecutive adult patients with chronic hepatitis C who achieved SVR with DAAs from August/2017 to December/2018 at Hospital Italiano de Buenos Aires (Argentina). To evaluate HRQL, SF-12v2® Health Survey (SF-12v2) was administered before treatment, at its end, and 12-16 weeks after treatment ended (follow-up visit). QualityMetric-2009 General Population Sample was used as a reference to compare summary scores. The survey has two main summary domains: the physical component summary score (PCS) and the mental component summary score (MCS). Changes over time > 3 points are considered significant. Results: A total of 159 patients were included, median age 59 (50- 69) years-old, 103 (65%) had cirrhosis [85 (83%) Child A; 18 (17%) Child B]. Most patients (80%) received daclatasvir plus sofosbuvir, with or without ribavirin. Median treatment duration was 12 (12-24) weeks. At baseline, both PCS and MCS were below the mean reference of the standard population and showed a significant and progressive improvement over time. The overall mean change on PCS from basal visit to follow-up visit was 4.33 points (95% CI: 2.93-5.73 points). The overall mean change on MCS from pre-treatment visit to follow-up visit was 4.89 points (95% CI: 2.75-6.53 points). In the subgroup of patients with cirrhosis, a significant improvement in both PCS and MCS was also observed. (Figure). Conclusion: HRQL significantly improved in Latin-American patients with CHC who achieved SVR with DAAs, even in those with cirrhosis.